Emerging clinical applications of exosomes in breast cancer management from biomarkers to therapeutics

外泌体在乳腺癌管理中的新兴临床应用:从生物标志物到治疗方法

阅读:2

Abstract

Exosomes, nano-sized extracellular vesicles carrying distinct molecular cargoes inherited from their parent cells, have emerged as critical mediators of intercellular communication in cancer. In breast cancer, tumor-derived exosomes (TDEs) possess unique molecular signatures and demonstrate remarkable potential in reshaping the tumor microenvironment, modulating immune responses, and driving disease progression. Growing evidence supports the diagnostic utility of TDEs in early detection and molecular subtyping of breast cancer, particularly via non-invasive liquid biopsy approaches. Meanwhile, exosomes in the breast cancer tumor microenvironment mediate intercellular communication and transmit pro-tumorigenic signals among various cell populations, thereby playing a pivotal role in promoting cell proliferation, angiogenesis, and tumor metastasis. On the therapeutic front, two strategies are attracting growing attention: inhibition of exosome biogenesis or reduction of circulating TDEs to disrupt tumor communication, and the engineering of exosomes as targeted delivery systems for drugs, RNAs, or immune modulators. Collectively, this review summarizes the current understanding of exosome biology in breast cancer and highlights the translational potential of both native and engineered exosomes as diagnostic and therapeutic tools. Continued research into exosome mechanisms and technologies will undoubtedly accelerate their integration into precision oncology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。